Recently, Japan has given two prominent topics, bad and good, to the global regenerative medicine community. The former is the over-promoted but fabricated STAP stem cell papers, and the latter is a rather unusual bold move by Japanese government to start flexible and relaxed regulation to advance the stem cell-based therapy. Then, what are happening in Japan?